Mind Medicine (MindMed) Inc.

WHO'M
ai
Digital Profiler. Simply click the AI button
CUSIP
60255C885
SEDOL
N/A
CIK
0001813814
www.mindmed.co
LEI:
©
FIGI: BBG00F13HYQ7
MNMD
Mind Medicine (MindMed) Inc.
GICS: - · Sector: Healthcare · Sub-Sector: Biotechnology
NAME
Mind Medicine (MindMed) Inc.
ISIN
CA60255C8850
TICKER
MNMD
MIC
XNAS
REUTERS
MNMD.OQ
BLOOMBERG
MNMD US
BUILD THEMEFOLIO SHARE IDEAS DISCUSS
LEVERAGE INVEST
EN 728x90
Financial Intelligence
360° iHub Crowd iFeed ATH Tracker Index Tracker ETF TF Spicy2 X-Billboard
FOR INVESTORS
FOR TRADERS
Securities Trading Warrants
The X-News Explorer is the ultimate source of information for investors with an affinity for the stock market who want to get a quick and convenient overview of the current news situation of a listed company. Various newswire services are available to you here. If a news alert is displayed, you will find company news that may be of interest to you. This service is provided by BusinessWire.
Mon, 18.11.2024       Mind Medicine
CA60255C8850

Mind Medicine (MindMed) Inc. (NASDAQ: MNMD), (the "Company" or "MindMed"), a clinical-stage biopharmaceutical company developing novel product candidates to treat brain health disorders, today announced the appointment of Gregg A. Pratt, Ph.D., as Chief Regulatory and Quality Assurance Officer. Dr. Pratt will serve as a member of the Executive Com...
Read More
Mind Medicine
Technical Analysis Termsheet Terminal
Permalink
Wed, 13.11.2024       Mind Medicine
CA60255C8850

Mind Medicine (MindMed) Inc. (NASDAQ: MNMD) (the “Company” or “MindMed”), a clinical-stage biopharmaceutical company developing novel product candidates to treat brain health disorders, today announced that members of the Company’s management team will participate in the following investor conferences: Jefferies London Healthcare Conference F...
Read More
Mind Medicine
Technical Analysis Termsheet Terminal
Permalink
Thu, 07.11.2024       Mind Medicine
CA60255C8850

Mind Medicine (MindMed) Inc. (NASDAQ: MNMD), (the "Company" or "MindMed"), a clinical-stage biopharmaceutical company developing novel product candidates to treat brain health disorders, today announced its financial results for the quarter ended September 30, 2024, and provided a business update. “This is a pivotal moment for MindMed as we prepa...
Read More
Mind Medicine
Technical Analysis Termsheet Terminal
Permalink
Thu, 24.10.2024       Mind Medicine
CA60255C8850

Mind Medicine (MindMed) Inc. (NASDAQ: MNMD) (the “Company” or “MindMed”), a clinical-stage biopharmaceutical company developing novel product candidates to treat brain health disorders, today announced that it plans to host a conference call on Thursday, November 7, 2024, at 4:30 p.m. ET to provide a corporate update and review the Company’s resul...
Read More
Mind Medicine
Technical Analysis Termsheet Terminal
Permalink
Mon, 09.09.2024       Mind Medicine
CA60255C8850

Mind Medicine (MindMed) Inc. (NASDAQ: MNMD) (the “Company” or “MindMed”), a clinical-stage biopharmaceutical company developing novel product candidates to treat brain health disorders, today announced the issuance of inducement grants to three newly hired non-executive employees consisting of options to purchase an aggregate of 70,000 common shar...
Read More
Mind Medicine
Technical Analysis Termsheet Terminal
Permalink
Wed, 04.09.2024       Mind Medicine
CA60255C8850

Mind Medicine (MindMed) Inc. (NASDAQ: MNMD) (the “Company” or “MindMed”), a clinical-stage biopharmaceutical company developing novel product candidates to treat brain health disorders, today announced that members of the Company’s management team will participate in the following investor conferences: H.C. Wainwright 26th Annual Global Investm...
Read More
Mind Medicine
Technical Analysis Termsheet Terminal
Permalink
Tue, 13.08.2024       Mind Medicine
CA60255C8850

Mind Medicine (MindMed) Inc. (NASDAQ: MNMD), (the "Company" or "MindMed"), a clinical-stage biopharmaceutical company developing novel product candidates to treat brain health disorders, today announced its financial results for the quarter ended June 30, 2024, and provided a business update. “Building on the positive momentum from our Phase 2b ...
Read More
Mind Medicine
Technical Analysis Termsheet Terminal
Permalink
Fri, 09.08.2024       Mind Medicine
CA60255C8850

Mind Medicine (MindMed) Inc. (NASDAQ: MNMD) (the “Company” or “MindMed”), a clinical stage biopharmaceutical company developing novel product candidates to treat brain health disorders, today announced the pricing of an underwritten public offering of 9,285,511 common shares, without par value, at a public offering price of $7.00 per common share,...
Read More
Mind Medicine
Technical Analysis Termsheet Terminal
Permalink
Fri, 09.08.2024       Mind Medicine
CA60255C8850

Mind Medicine (MindMed) Inc. (NASDAQ: MNMD) (the “Company” or “MindMed”), a clinical stage biopharmaceutical company developing novel product candidates to treat brain health disorders, today announced that it intends to offer and sell, subject to market conditions, common shares and, to certain investors, pre-funded warrants to purchase common sh...
Read More
Mind Medicine
Technical Analysis Termsheet Terminal
Permalink
We are different
OPEN FINANCIAL
DATA & KNOWLEDGE HUB
We make the difference
Information on product placements